Moving forward with focus, discipline, and confidence

Across Pharma Systems, I continue to be encouraged by what I see every day: strong execution, growing customer trust, and teams that are deeply committed to doing the right things well. We are operating in a demanding environment, but we are also building momentum where it matters most. Our performance reflects that balance. Outside vaccines, the business continues to show resilience and strength, supported by biologics growth, high service levels, and disciplined execution across functions. Customers are increasingly engaging us as a trusted partner, not only because of our products, but because of how reliably and professionally we deliver.

That trust has been earned through consistency. Quality, supply reliability, and responsiveness are not abstract concepts, they are the result of thousands of decisions made every day by our teams in operations, quality, supply chain, commercial, R&D, and support functions. This foundation gives us confidence as we look ahead.

At the same time, we must remain clear eyed about the challenges we face. The vaccine market continues to be under pressure, with real implications for revenue and profitability. This requires discipline and focus across the organization. Every investment, every cost, and every priority must be viewed through the lens of long-term value creation. Red indicators are not failures. They are signals that tell us where to act, where to simplify, and where to be sharper.

One area where alignment is absolute is contamination control. This is not a quality topic alone. It is a business priority that directly affects patient safety, customer trust, operational efficiency, and our competitive position. When we execute well, we reduce the cost of poor quality, free up capacity for higher value work, and clearly differentiate BD in the market. I want to thank everyone working on this effort across sites and functions. The responsibility is significant, and so is the impact - for our customers and patients.

I am also encouraged by the progress we are making in innovation and culture. We are simplifying how we work (but not fast enough!), accelerating development where it matters, and engaging customers earlier and more effectively. At the same time, our culture journey is becoming tangible in daily behaviors: stronger collaboration, clearer ownership, and greater confidence in decision making.

We will not succeed through individual efforts or siloed excellence. We succeed when we act as one organization, aligned on priorities, disciplined in execution, and committed to continuous improvement.

Lastly, I also want to point out talent development as an area of focus. Every organizational update over the last months has given us opportunities to simplify, increase our subject matter expertise and promote our strong talents.

Thank you for your resilience during times of change, your professionalism, and your contribution to building a stronger Pharma Systems every day. FutureUp!

Warm regards,

Patrick Jeukenne

Worldwide President of Pharma Systems

Watch the recap video

Progress, Priorities and What Comes Next

The Global Pharma Systems Town Hall brought associates and leaders together around a shared reality: the business is growing within a demanding environment, our fundamentals (Quality, Supply Chain, R&D) are improving, the market is shifting, and the path forward requires focus, discipline, and teamwork. The session balanced progress with pragmatism, reinforcing what will matter most in the months ahead.

Your questions, answered

During the recent Global PS Town Hall, associates asked thoughtful, direct questions about our strategy, markets, investments, and ways of working. While not all questions could be addressed live, we have captured and answered many of them here. This Q&A offers clarity on what is changing, what is not, and how Pharmaceutical Systems is positioned for the future.

How GLP1s, biologics and new technologies are reshaping our market

The rapid growth of biologics, led by GLP1 therapies, is reshaping healthcare at an unprecedented pace. From injectable and oral drug delivery to digital ecosystems, manufacturing scale-up and the use of advanced analytics and AI, these shifts are redefining expectations across the pharmaceutical value chain. Explore the articles most relevant to your interests!

BD iDFill™ Launches: Turning Every Syringe
into a Digital Enabler

After five years of deep collaboration across BD Pharmaceutical Systems, a new chapter in fill finish innovation officially begins. On February 19, BD iDFill™ was released for sale, marking a major milestone in BD's journey to advance digital, data driven manufacturing for injectable drugs. BD iDFill is born. And this is only the beginning.

Watch the BD iDFill™ Tour Video!

BD Highlights Biologics Delivery Advances, Strong Customer Engagement at Pharmapack 2026

As highlighted in a recent BD Pharmaceutical Systems presented a series of new and emerging drug delivery innovations at Pharmapack 2026, emphasizing the company's continued investment in technologies designed for large volume biologics, GLP1 therapies and patient centric administration.

BD and Ypsomed Strengthen Collaboration to Advance Large-Volume Self Injection

As biologic therapies continue to transform the treatment of complex and chronic diseases, the demands placed on drug delivery systems are rising just as quickly. We see an urgent need for new solutions that balance performance with patient usability. To help address this challenge, BD and Ypsomed are expanding their longstanding collaboration with the development of a 5.5 mL version of the BD Neopak™ XtraFlow™ Glass Prefillable Syringe.

Read the press release

BD Secures Strategic GLP1 Partnership with Pfizer/Metsera

BD has secured a major strategic win in the rapidly growing GLP1 space, reinforcing our leadership in diabetes, obesity and NuSH therapies while reclaiming a program previously anchored on a competitor platform.

Why BD's $110 million investment
in Columbus matters

When BD announced a $110 million investment to expand manufacturing in Columbus, Nebraska, it was about more than adding new production lines. It was a strategic move tied directly to where our industry is heading and how we are preparing for what comes next.

Protecting Patients Starts with
Contamination Control

In every injection, there is a moment of trust. Patients trust that the medicines they receive are safe, pure, and effective. Healthcare providers trust that every component of a drug delivery system performs exactly as intended. And at BD Pharmaceutical Systems, we understand that this trust is earned through an uncompromising focus on quality, product safety, and contamination control.

BD & Sandoz Partner on Renewable Energy Initiative to Advance Climate Goals

From ambitious climate targets to renewable electricity in practice, BD is accelerating its sustainability journey through collaboration. A growing partnership with Sandoz shows how working together can unlock momentum, reduce emissions, and deliver impact that matters.

Sustainability that customers can see,
trust, and use

Sustainability is no longer a “nice to have” for customers. It is increasingly part of how they assess partners, manage risk, and make longterm decisions. That reality is driving the launch of the BD Sustainability Digital Campaign, which brings together clear, factbased proof of how BD is advancing sustainability while delivering real value to customers.

From everyday life to exceptional journeys: celebrating International Women's Day at BD France

To mark International Women's Day, BD France hosted a series of inspiring events on March 9 across its Spring and Pont-de-Claix sites, bringing colleagues together to celebrate women's voices, experiences, and contributions.

Rapid-fire conversations with purpose: Patrick Jeukenne connects with PS associates in FLKS

An experiment in open dialogue and connection paid off recently in Franklin Lakes, as PS associates took part in an interactive “rapid-fire” conversation session with Patrick Jeukenne, Worldwide President, Pharmaceutical Systems. The session combined an informal Town Hall discussion with a series of small-group, rotating conversations designed to encourage candid exchange.